Notable Labs

Notable Labs Book Value per Share

The Book Value per Share of Notable Labs (NTBLQ) as of Nov 16, 2026 is 1.56 USD. In the previous year, Book Value per Share was 2.32 USD — a change of -32.68% (lower).

Book Value per Share

1.56USD

YoY

-32.68%

Last updated:

Book Value per Share of Notable Labs is 2023 1.56 USD. Book Value per Share of Notable Labs was 2022 2.32 USD. It decreases by -32.68% lower compared to the previous year.

The Notable Labs Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2016
4.39 USD
Jan 1, 2017
5.79 USD
Jan 1, 2018
5.50 USD
Jan 1, 2019
3.73 USD
Jan 1, 2020
3.20 USD
Jan 1, 2021
5.40 USD
Jan 1, 2022
2.32 USD
Jan 1, 2023
1.56 USD
The Notable Labs Book Value per Share history
YEARBook Value per ShareYoY
1.56USD-32.68%
2.32USD-56.98%
5.40USD+68.76%
3.20USD-14.16%
3.73USD-32.15%
5.50USD-5.03%
5.79USD+31.84%
4.39USD+21.11%
3.62USD-0.26%
3.63USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Book Value per Share of Notable Labs is 1.56 USD in 2023.

Book Value per Share of Notable Labs changed from 2.32 USD to 1.56 USD, representing a -32.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Notable Labs

All Key Metrics — Notable Labs